Literature DB >> 17981213

p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia.

Onoshua Lahiri1, Scott Harris, Graham Packham, Melanie Howell.   

Abstract

The p53 pathway plays a critical role in chronic lymphocytic leukemia (CLL). The association between the single-nucleotide polymorphism (SNPs) within the p53 gene (R72P) and its downstream target/regulators, BAX (G125A) and MDM2 (SNP309), and clinical parameters/prognostic markers was investigated in 83 CLL patients. Although the p53 R72P SNPs and MDM2 SNP309 did not associate with any of the parameters studied, the BAX G125A SNPs was associated with a more advanced Binet stage at diagnosis, supporting a potential role for this variant in CLL disease progression. In reporter assays, however, the BAX 5' untranslated region G125A SNPs surprisingly caused a 1.8-fold increase in basal promoter activity and did not alter the ability of p53 to trans-activate the promoter. Further studies are required to understand the role of SNPs in the p53 pathway in CLL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981213     DOI: 10.1016/j.cancergencyto.2007.07.013

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia.

Authors:  Hua-Jie Dong; Cheng Fang; Li Wang; Lei Fan; Ji Xu; Jia-Zhu Wu; Ting-Xun Lu; Jian-Yong Li; Wei Xu
Journal:  Med Oncol       Date:  2014-03-11       Impact factor: 3.064

2.  MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.

Authors:  Axel Benner; Larry Mansouri; Davide Rossi; Aneela Majid; Kerstin Willander; Anton Parker; Gareth Bond; Sarka Pavlova; Holger Nückel; Olaf Merkel; Paolo Ghia; Emili Montserrat; Mohd Arifin Kaderi; Richard Rosenquist; Gianluca Gaidano; Martin J S Dyer; Peter Söderkvist; Mats Linderholm; David Oscier; Zuzana Tvaruzkova; Sarka Pospisilova; Ulrich Dührsen; Richard Greil; Hartmut Döhner; Stephan Stilgenbauer; Thorsten Zenz
Journal:  Haematologica       Date:  2014-08       Impact factor: 9.941

Review 3.  Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.

Authors:  Sean M Post; Vinod Pant; Hussein Abbas; Alfonso Quintás-Cardama
Journal:  Oncotarget       Date:  2010-07

4.  Evaluation of Bax and Bak gene mutations and expression in breast cancer.

Authors:  Naglaa Mohamed Kholoussi; Sobhy E H El-Nabi; Nora Nassef Esmaiel; Naser Mohamed Abd El-Bary; Ahmed F El-Kased
Journal:  Biomed Res Int       Date:  2014-02-09       Impact factor: 3.411

5.  TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population

Authors:  Ameen Abdulaziz Mohammed Basabaeen; Enaam Abdalrhman Abdelgader; Ebtihal Ahmed Babekir; Saadia Osman Abdelrahim; Nada Hassan Eltayeb; Osama Ali Altayeb; Eman Abbass Fadul; Abdulwali Sabo; Ibrahim Khider Ibrahim
Journal:  Asian Pac J Cancer Prev       Date:  2019-05-25

6.  p53 p.Pro72Arg (rs1042522) and Mouse Double Minute 2 (MDM2) Single-Nucleotide Polymorphism (SNP) 309 Variants and Their Interaction in Chronic Lymphocytic Leukemia(CLL): A Survey in CLL Patients from Western Iran.

Authors:  Nazanin Jalilian; Yosra Maleki; Ebrahim Shakiba; Mozafar Aznab; Ziba Rahimi; Mehdi Salimi; Zohreh Rhimi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2021-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.